Pfizer Inc on Tuesday reported first-quarter profit that beat Wall Street estimates, as strong demand for its recently acquired products and pneumococcal vaccines helped offset the impact from declining sales of its COVID-19 products.
Excluding items, the U.S. drugmaker earned $1.23 per share for the quarter ended March 31, compared with estimates of 98 cents, according to Refinitiv estimates.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments